Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 744 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol (Oral) Clear all
Recruiting Not applicable Interventional

Barotrauma in Hyperbaric Oxygen Therapy

NCT05697328
View directory record Official record
Conditions
Barotrauma
Interventions
Pseudoephedrine Pill, Placebo
Drug
Lead sponsor
John Muir Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Early Phase 1 Interventional Results available

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

NCT04088630
View directory record Official record
Conditions
Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
Interventions
Fingolimod, Placebo, Open-label Fingolimod
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional

Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)

NCT02624765
View directory record Official record
Conditions
Fetal Atrial Flutter Without Hydrops, Fetal Supraventricular Tachycardia Without Hydrops, Fetal Supraventricular Tachycardia With Hydrops
Interventions
Digoxin (monotherapy), Sotalol (monotherapy), Flecainide (monotherapy), Digoxin (dual therapy), Sotalol (dual therapy), Flecainide (dual therapy)
Drug
Lead sponsor
Edgar Jaeggi
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

NCT00935220
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin QD (once daily) for 7 days
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
21 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Cypress, California • DeLand, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Pediatric CBD Program

NCT02695537
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 19 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans

NCT03039023
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Choline Bitartrate, Pre-cooked, pre-peeled whole hardboiled eggs, Egg whites from pre-cooked, pre-peeled hardboiled eggs, Phosphatidylcholine capsules
Dietary Supplement · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

MGR001 / Advair Diskus Local Equivalence Study in Asthma

NCT02245672
View directory record Official record
Conditions
Asthma
Interventions
MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Mylan Pharma UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

NCT03367533
View directory record Official record
Conditions
Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder
Interventions
Ketamine, Perampanel, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 4 Interventional

Study of Aripiprazole in Subjects With Alcoholism

NCT00082199
View directory record Official record
Conditions
Alcoholism
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
14
States / cities
Farmington, Connecticut • New Haven, Connecticut • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Propranolol in Treating Hypoglycemia Unawareness

NCT03161964
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Propranolol 80 Mg Oral Capsule, Extended Release, Placebo oral capsule
Drug
Lead sponsor
Anu Sharma
Other
Eligibility
21 Years to 59 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Zonisamide for Heavy Drinkers With Bipolar Disorder

NCT01566370
View directory record Official record
Conditions
Alcohol Use Disorders, Bipolar Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 17, 2026, 4:30 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

NCT07269873
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
Drug
Lead sponsor
BioCorRx Pharmaceuticals Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Results available

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356
View directory record Official record
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Not yet recruiting Phase 2 Interventional

Combination Therapy for Alcohol Use Disorder

NCT07249554
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Havre de Grace, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00355134
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
100
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)

NCT00803634
View directory record Official record
Conditions
Hypertension, Heart Failure
Interventions
Clevidipine, Standard of Care IV antihypertensive
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

NCT02954887
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolism in the Human Brain Following Consumption of a Keto-ester in Alcohol Use Disorder (AUD) With Proton Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT05937893
View directory record Official record
Conditions
BHB Transport, Alcohol Use Disorder
Interventions
Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Study of Thyroid Hormones in Prematures

NCT02103998
View directory record Official record
Conditions
Transient Hypothyroxinemia of Prematurity (THOP)
Interventions
thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Hour to 24 Hours
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 4 Interventional Results available

Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients

NCT01157234
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling

NCT02654236
View directory record Official record
Conditions
Alcohol Consumption
Interventions
Placebo, 10 mg Obeticholic Acid (OCA)
Drug
Lead sponsor
Suthat Liangpunsakul
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional Results available

Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD

NCT02226367
View directory record Official record
Conditions
Alcohol Use Disorders, Stress Disorders, Posttraumatic, Combat Disorders
Interventions
prazosin hydrochloride, placebo
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
21 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 17, 2026, 4:30 PM EDT